(87 days)
3Di is intended for use as an interactive tool for assisting professional Radiologists, Cardiologists and specialists to reach their own diagnosis, by providing tools of communication, clinics networking, WEB Serving, image viewing, image manipulation, 2D/3D image visualization, image processing, reporting and archiving. The 3Di indications for use are processing of Cardiac CT studies, including CT Calcium scoring, CT Cardiac angiography, coronaries analysis, cardiac functional assessment and of CT colonoscopy. The 3Di indications for use have been modified to include viewing of Mammography images.
3Di is a PACS device which enables users to access medical images over a network and to utilize 3Di's image visualization tools to review the images. It provides the following functions: Web server, patient browser, PACS capabilities, multi-modality viewing, CT Cardiac and Colonoscopy clinical applications. The 3Di indications for use have been modified to include viewing of Mammography images.
The provided text describes the 3Di device, a PACS workstation that now includes the viewing of Mammography images. The submission focuses on demonstrating substantial equivalence for this added functionality.
1. Table of Acceptance Criteria and Reported Device Performance
| Acceptance Criteria | Reported Device Performance |
|---|---|
| Quality of Mammography imaging is unsubstantially different or equivalent to DICOM source mammographic data (for accurate viewing) | The quality of Mammography imaging was validated by comparing the device imaging output to the DICOM source mammographic data. The comparison results demonstrate that the 3Di and the DICOM source mammographic data are substantial equivalent in terms of image quality. |
2. Sample Size Used for the Test Set and Data Provenance
The document does not explicitly state the sample size used for the test set or the data provenance (e.g., country of origin, retrospective/prospective). It only mentions "comparison results" without detailing the number of mammography images or studies included in this comparison.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts
The document does not specify the number of experts used or their qualifications for establishing ground truth for the test set. It only mentions that the device is "intended for use as an interactive tool for assisting professional Radiologists, Cardiologists and specialists to reach their own diagnosis".
4. Adjudication Method for the Test Set
The document does not describe any specific adjudication method (e.g., 2+1, 3+1) used for the test set. The validation was based on a direct comparison of image quality.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study
No multi-reader multi-case (MRMC) comparative effectiveness study is mentioned in the provided text. The submission focuses on the equivalency of image quality for mammography viewing, not on the impact of the AI on human reader performance or diagnostic accuracy.
6. Standalone Performance Study
No standalone (algorithm only without human-in-the-loop performance) study is explicitly detailed. The validation described is a comparison of image output quality of the device against the DICOM source, rather than an algorithmic diagnostic performance study.
7. Type of Ground Truth Used
The "ground truth" for the validation seems to be the DICOM source mammographic data itself. The device's output was compared directly against this source data to ensure visual fidelity and quality. This indicates a technical ground truth related to image rendering, rather than a clinical ground truth like pathology or expert consensus on disease presence.
8. Sample Size for the Training Set
The document does not provide any information about a training set since the validation focuses on image quality comparison, not on a machine learning model that would require a training set.
9. How the Ground Truth for the Training Set Was Established
Not applicable, as no training set or related ground truth establishment is mentioned in the context of this 510(k) submission.
{0}------------------------------------------------
Page 1 of 1
510(k) Summary of Safety and Effectiveness (in accordance to 21 CFR 807.87(h)
Device Name
Proprietary Device Name: 3Di including Viewing of Mammography images
Establishment Name and Registration Number of Submitter
Name: Shina Systems Ltd. Corresponding Official: Dan Laor Sireni 6, Haifa 32972, Israel TEL: +972-4-8246632
Device Classification
| Product Code: | LLZ |
|---|---|
| CFR section: | 892.2050 |
| Panel Identification: | Radiology |
| Device Description: | Picture archiving and communications system |
| Classification: | II |
Reason for 510(k) Submission
Traditional 510(k) Submission
Identification of Legally Marketed Predicate Devices
K112530 3Di
Device Description
3Di is a PACS device which enables users to access medical images over a network and to utilize 3Di's image visualization tools to review the images. It provides the following functions: Web server, patient browser, PACS capabilities, multi-modality viewing, CT Cardiac and Colonoscopy clinical applications. The 3Di indications for use have been modified to include viewing of Mammography images.
Intended use and indications for Use
3Di is a software package of PACS workstation for handling multimodality (CT, XA, MR, PET, SPECT, Ultrasound &Mammography) images, which are using DICOM protocol. It includes volume rendering, Multi-planar reconstruction (MPR) and viewing of the inner and outer surfaces of organs as well as within their walls. 3Di is intended for use as an interactive tool for assisting professional Radiologists, Cardiologists and specialists to reach their own diagnosis, by providing tools of communication, clinics networking, WEB Serving, image viewing, image manipulation, 2D/3D image visualization, image processing, reporting and archiving. The 3Di indications for use are processing of Cardiac CT studies, including CT Calcium scoring, CT Cardiac angiography, coronaries analysis, cardiac functional assessment and of CT colonoscopy.
Safety & Effectiveness
The device has been designed, verified and validated complying to 21CFR 820.30 regulations. The device has been designed to meet the requirements of ISO 14971 Safety standard. The quality of Mammography imaging has been validated by comparison the device imaging output to the DICOM source mammographic data. The comparison results demonstrate that the 3Di and the DICOM source mammographic data are substantial equivalent in terms of image quality.
Substantial Equivalency
It is Shina System opinion that the 3Di is substantially equivalent in terms of safety and effectiveness to the predicate device.
{1}------------------------------------------------
Image /page/1/Picture/0 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a stylized eagle with three stripes forming its body and wings. The eagle faces right. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the eagle.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room - WO66-G609 Silver Spring, MD 20993-0002
FEB 1 6 2012
Shina Systems Ltd. % Mr. Dan Laor Quality and Regulatory Advisor Sireni 6 32972 HAIFA ISRAEL
Re: K113442
Trade/Device Name: 3Di Regulation Number: 21 CFR 892.2050 Regulation Name: Picture archiving and communications system Regulatory Class: II Product Code: LLZ Dated: November 9, 2011 Received: November 21, 2011
Dear Mr. Laor:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of
{2}------------------------------------------------
medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket with and would began finding of substantial equivalence of your device to a legally marketed nredicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely Yours,
Mary Pastel
Mary S. Pastel, Sc.D. Director Division of Radiological Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
{3}------------------------------------------------
K113442 Page 1 of 1
Indications for Use
510(k) Number (if known): K113442
Device Name: 3Di
Indications For Use:
3Di is a software package of PACS workstation for handling multimodality (CT, XA, MR, PET, SPECT, Ultrasound & Mammography) images, which are using DICOM protocol. It includes volume rendering, Multi-planar reconstruction (MPR) and viewing of the inner and outer surfaces of organs as well as within their walls.
3Di is intended for use as an interactive tool for assisting professional Radiologists, Cardiologists and specialists to reach their own diagnosis, by providing tools of communication, clinics networking, WEB Serving, image viewing, image manipulation, 2D/3D image visualization, image processing, reporting and archiving. The 3Di indications for use are processing of Cardiac CT studies, including CT Calcium scoring, CT Cardiac angiography, coronaries analysis, cardiac functional assessment and of CT colonoscopy.
X Prescription Use (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Mary S. Patil
(Division Sign Off)
(DMsion Sign-On)
Division of Radiological Devices
Office of In Vitro Diagnostic Device Evaluation and Safety
BLOK
K113442
ਜੋਂ Page 1 of
§ 892.2050 Medical image management and processing system.
(a)
Identification. A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.(b)
Classification. Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).